At the Modena University Hospital, a Seminar by Dr Brydon Bennett on the Drug Development Process
The event will take place in the Building of Morphological and Forensic Medical Sciences and is organised by the Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine of the University of Modena and Reggio Emilia (Unimore).
The seminar will explore how new drugs are designed using the ECA model, which is based on the concept of a “diamond” with its various “facets” and “properties.” As an example, Dr Bennett will present CC-90001, a drug that inhibits the JNK1 protein. He was the project lead for its development, and the compound has already successfully completed Phase 2a clinical trials.
Dr Brydon Bennett has more than 20 years’ experience in pharmaceutical research. He has published over 50 scientific papers and is the inventor of several patents. He began his career at Signal Pharmaceuticals in 1997, a company later acquired by Celgene, where he led research projects focused on inflammation and immunology. The projects he directed reached all stages of clinical development. In 2018, he left Celgene to pursue entrepreneurial ventures in drug discovery. He earned both his degree and PhD from the University of Otago (New Zealand) and carried out postdoctoral research in the United States.
“This important event provides an excellent opportunity to explore the topic of drug development from the initial selection of candidates through preclinical testing — in silico, in vitro and in vivo — aimed at demonstrating the mechanism of action,” said Professor Alessandra Marconi, Head of the DermoLAB at Unimore and organiser of the seminar. “Dr Brydon Bennett, a highly experienced expert in pharmaceutical development and translational research, has contributed to bringing numerous compounds into clinical trials. During the seminar, he will guide us through the preclinical development process, with a particular focus on the JNK1 inhibitor case study. Brydon, in addition to being a dear friend, is also an active collaborator in the development of PinCell S.r.l., an academic spin-off established at Unimore.”
The seminar is primarily aimed at students and researchers interested in drug discovery and cutting-edge biomedical research.
Categorie: International - english, Notizie_eng
Articolo pubblicato da: Ufficio Stampa Unimore - ufficiostampa@unimore.it